ErbB 4 increases the proliferation potential of human lung cancer cells and its blockage can be used as a target for anti-cancer therapy
暂无分享,去创建一个
Y. Yarden | J. Greif | M. Inbar | A. Vexler | S. Lev-Ari | R. Ben-Yosef | C. Rubin | A. Starr | Maia Ashkenazy-Voghera | Valery Gladesh | G. Kerber | S. Marmor | R. Ben‐Yosef
[1] Y. Yarden,et al. Synergistic down-regulation of receptor tyrosine kinases by combinations of mAbs: implications for cancer immunotherapy. , 2005, Proceedings of the National Academy of Sciences of the United States of America.
[2] A. Ardizzoni,et al. Epidermal growth factor receptor inhibitors: a new prospective in the treatment of lung cancer. , 2004, Current medicinal chemistry. Anti-cancer agents.
[3] J. R. Reeves,et al. Expression of the HER1–4 family of receptor tyrosine kinases in breast cancer , 2003, The Journal of pathology.
[4] B. Angus,et al. Type 1 growth factor receptor expression in node positive breast cancer: adverse prognostic significance of c-erbB-4 , 2003, Journal of clinical pathology.
[5] D. Riese,et al. A constitutively active ErbB4 mutant inhibits drug-resistant colony formation by the DU-145 and PC-3 human prostate tumor cell lines. , 2003, Cancer letters.
[6] G. Carpenter,et al. ErbB-4: mechanism of action and biology. , 2003, Experimental cell research.
[7] T. Curran,et al. ERBB receptor signaling promotes ependymoma cell proliferation and represents a potential novel therapeutic target for this disease. , 2002, Clinical cancer research : an official journal of the American Association for Cancer Research.
[8] M. Inbar,et al. ErbB-4 expression in limb soft-tissue sarcoma: correlation with the results of neoadjuvant chemotherapy. , 2002, European journal of cancer.
[9] J. Nesland,et al. EGFR family expression in breast carcinomas. c‐erbB‐2 and c‐erbB‐4 receptors have different effects on survival , 2002, The Journal of pathology.
[10] R. Allibone,et al. Novel ERBB4 juxtamembrane splice variants are frequently expressed in childhood medulloblastoma , 2001, Genes, chromosomes & cancer.
[11] J. Greif,et al. Correlation between c-erbB-4 receptor expression and response to gemcitabine-cisplatin chemotherapy in non-small-cell lung cancer. , 2001, Annals of oncology : official journal of the European Society for Medical Oncology.
[12] J. Smyth,et al. Expression of erbB-4/HER-4 growth factor receptor isoforms in ovarian cancer. , 2001, Cancer research.
[13] O. Stoeltzing,et al. Multiple molecular marker testing (p53, C-Ki-ras, c-erbB-2) improves estimation of prognosis in potentially curative resected non-small cell lung cancer , 2000, British Journal of Cancer.
[14] R. Narayanan,et al. HER-2/neu expression in archival non-small cell lung carcinomas using FDA-approved Hercep test. , 2000, Anticancer research.
[15] M. Klagsbrun,et al. A Natural ErbB4 Isoform That Does Not Activate Phosphoinositide 3-Kinase Mediates Proliferation but Not Survival or Chemotaxis* , 2000, The Journal of Biological Chemistry.
[16] D. Barnes,et al. Nuclear expression of the c-erbB-4/HER-4 growth factor receptor in invasive breast cancers. , 2000, Cancer research.
[17] M. Sliwkowski,et al. Biologic effects of heregulin/neu differentiation factor on normal and malignant human breast and ovarian epithelial cells , 1999, Oncogene.
[18] W. Gullick,et al. Expression of the c-erbB-3/HER-3 and c-erbB-4/HER-4 Growth Factor Receptors and Their Ligands, Neuregulin-1 α, Neuregulin-1 β, and Betacellulin, in Normal Endometrium and Endometrial Cancer , 1999 .
[19] H. Friess,et al. ErbB‐4 mRNA expression is decreased in non‐metastatic pancreatic cancer , 1999, International journal of cancer.
[20] M. Kraus,et al. Immune responses to all ErbB family receptors detectable in serum of cancer patients , 1999, Oncogene.
[21] I. Ellis,et al. c-erbB3 and c-erbB4 expression is a feature of the endocrine responsive phenotype in clinical breast cancer , 1998, Oncogene.
[22] J. Lunec,et al. Expression of the ErbB-neuregulin signaling network during human cerebellar development: implications for the biology of medulloblastoma. , 1998, Cancer research.
[23] L. Norton,et al. Recombinant humanized anti-HER2 antibody (Herceptin) enhances the antitumor activity of paclitaxel and doxorubicin against HER2/neu overexpressing human breast cancer xenografts. , 1998, Cancer research.
[24] R. Poulsom,et al. Expression of the c‐erbB‐4/HER4 protein and mRNA in normal human fetal and adult tissues and in a survey of nine solid tumour types , 1998, The Journal of pathology.
[25] D. Stern,et al. Activation of ErbB4 by the Bifunctional Epidermal Growth Factor Family Hormone Epiregulin Is Regulated by ErbB2* , 1998, The Journal of Biological Chemistry.
[26] R. Sutherland,et al. Granulosa cell tumors express erbB4 and are sensitive to the cytotoxic action of heregulin-beta2/PE40. , 1998, Cancer research.
[27] K. Kelly,et al. New chemotherapeutic agents prolong survival and improve quality of life in non-small cell lung cancer: a review of the literature and future directions. , 1998, Clinical cancer research : an official journal of the American Association for Cancer Research.
[28] R H Perry,et al. Prognostic significance of HER2 and HER4 coexpression in childhood medulloblastoma. , 1997, Cancer research.
[29] M. Klagsbrun,et al. Activation of HER4 by heparin‐binding EGF‐like growth factor stimulates chemotaxis but not proliferation , 1997, The EMBO journal.
[30] O. Bogler,et al. A common mutant epidermal growth factor receptor confers enhanced tumorigenicity on human glioblastoma cells by increasing proliferation and reducing apoptosis. , 1996, Cancer research.
[31] Y. Yarden,et al. Neu differentiation factor (Heregulin) activates a p53-dependent pathway in cancer cells. , 1996, Oncogene.
[32] Y. Yarden,et al. An Immunological Approach Reveals Biological Differences between the Two NDF/Heregulin Receptors, ErbB-3 and ErbB-4 (*) , 1996, The Journal of Biological Chemistry.
[33] L. Akslen,et al. Expression of c-erbB-3 and c-erbB-4 proteins in papillary thyroid carcinomas. , 1996, Cancer research.
[34] Y. Yarden,et al. Type 1 receptor tyrosine kinases are differentially phosphorylated in mammary carcinoma and differentially associated with steroid receptors. , 1996, The American journal of pathology.
[35] T. van Raaij,et al. Betacellulin activates the epidermal growth factor receptor and erbB-4, and induces cellular response patterns distinct from those stimulated by epidermal growth factor or neuregulin-beta. , 1996, Oncogene.
[36] W. Richards,et al. Localized adenocarcinoma of the lung: oncogene expression of erbB-2 and p53 in 150 patients. , 1995, Clinical cancer research : an official journal of the American Association for Cancer Research.
[37] Y. Yarden,et al. Medullary carcinoma is associated with expression of intercellular adhesion molecule-1. Implication to its morphology and its clinical behavior. , 1994, The American journal of pathology.
[38] E. Peles,et al. ErbB-3 and ErbB-4 function as the respective low and high affinity receptors of all Neu differentiation factor/heregulin isoforms. , 1994, The Journal of biological chemistry.
[39] W. Cavenee,et al. A mutant epidermal growth factor receptor common in human glioma confers enhanced tumorigenicity. , 1994, Proceedings of the National Academy of Sciences of the United States of America.
[40] G. Plowman,et al. Heregulin induces tyrosine phosphorylation of HER4/p180erbB4 , 1993, Nature.
[41] G. Plowman,et al. Ligand-specific activation of HER4/p180erbB4, a fourth member of the epidermal growth factor receptor family. , 1993, Proceedings of the National Academy of Sciences of the United States of America.
[42] D. Weiner,et al. p185neu expression in human lung adenocarcinomas predicts shortened survival. , 1990, Cancer research.
[43] F. Hamdy,et al. THE NEW ENGLAND JOURNAL OF MEDICINE , 1977, The Lancet.
[44] H. Juhl,et al. Comparative analysis of the EGF-receptor family in pancreatic cancer: expression of HER-4 correlates with a favourable tumor stage. , 2001, International journal of surgical investigation.
[45] Taylor Murray,et al. Cancer Statistics, 2001 , 2001, CA: a cancer journal for clinicians.
[46] Y. Yarden,et al. Biochemical and clinical implications of the ErbB/HER signaling network of growth factor receptors. , 2000, Advances in cancer research.
[47] D. Stern,et al. Neuregulin activation of ErbB receptors in vascular endothelium leads to angiogenesis. , 1999, The American journal of physiology.
[48] M. O’Connor-McCourt,et al. Expression of P185erbB-2, P160erbB-3, P180erbB-4, and heregulin alpha in human normal bronchial epithelial and lung cancer cell lines. , 1999, Anticancer research.
[49] M. Melhem,et al. Tissue expression of neu differentiation factor/heregulin and its receptor complex in prostate cancer and its biologic effects on prostate cancer cells in vitro. , 1997, The cancer journal from Scientific American.
[50] M. Kelley,et al. Genetic mechanisms of solid tumor oncogenesis. , 1994, Advances in internal medicine.